Driven to lead the way

Patrick Jordan is Chairman of Mycovia Pharmaceuticals and Partner at NovaQuest Capital Management, a life sciences private equity firm where he creates and manages global biopharmaceutical investments. He has more than 25 years of healthcare leadership in corporate development, operations, provider services, and technology solutions. Prior to joining Mycovia and NovaQuest, Mr. Jordan spent 20 years at IQVIA (formerly Quintiles) in global leadership roles, and he instituted a managed partnership process with biopharmaceutical companies that was recognized internationally.  An original member of NovaQuest at its founding at Quintiles, Mr. Jordan led the group’s investment partnership strategy in Europe.

Mr. Jordan earned a BA from Duke University; an MA from the University of Durham, United Kingdom; and an MBA with a concentration in Health Sector Management from the Fuqua School of Business at Duke University.

Stephen Brand provides strategic direction and technical leadership to the clinical development and medical affairs teams. He is responsible for the overall management and performance of the company’s antifungal clinical development programs in women’s health and other areas. Dr. Brand most recently served as Vice President, Clinical Development at Viamet Pharmaceuticals where he led cross-functional project teams, resulting in the successful completion of Phase 2b studies in recurrent vulvovaginal candidiasis and onychomycosis. He previously served as President of Agile Sciences and Director at Argos Therapeutics. Dr. Brand has held senior positions in pharmaceutical development at BioStratum, Inc., and Cato Research Ltd.

Dr. Brand is a graduate member of the Institute of Biology (GiBiol) and holds a PhD in Molecular Biology from the School of Medicine, University of Manchester, England. He completed his post-doctoral fellowship at Cold Spring Harbor Laboratory, NY.

Thorsten Degenhardt provides technical and strategic leadership to the Mycovia Pharmaceuticals team and is responsible for all non-clinical development aspects of the company’s antifungal programs, including chemistry and manufacturing, pharmacology/toxicology, regulatory affairs and project management. Dr. Degenhardt previously served as VP Project Management at Viamet Pharmaceuticals, where he directed the company’s development programs. He previously served in multiple leadership positions at Cempra and BioStratum where he was responsible for all development aspects of their lead programs.

Dr. Degenhardt holds an MS in Biochemistry from the Technical University of Darmstadt and a PhD in pharmaceutical chemistry from Heidelberg University. He subsequently completed postdoctoral studies and worked as a Research Assistant Professor at the Department of Biochemistry at the University of South Carolina.

Rachel Gee provides strategic and operational leadership for the company while supporting business development and partnership activities. With more than 20 years of experience in the life sciences and pharmaceutical industry, Ms. Gee has a diverse background in regulatory, clinical, project management, and business development roles.  Ms. Gee most recently served as Director, Project Management and Regulatory Affairs at Viamet Pharmaceuticals where she was responsible for leading successful regulatory submissions and agency meetings, as well as driving the overall development timelines for multiple products within the antifungal program.  She has previously served VP, Project Management at Cato Research where she led the global project management department and clinical and regulatory programs for small biotech and large pharmaceutical clients.

Ms. Gee holds a BS in Zoology from North Carolina State University and is a member of the Association of Strategic Alliance Professionals, the Regulatory Affairs Professionals Society, and the Project Management Institute.